multicode-plx rvp (EraGen Biosciences)
90
Structured Review
EraGen Biosciences
multicode-plx rvp
Multicode Plx Rvp, supplied by EraGen Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multicode-plx/multicode+plx+rvp/pmc03280232-83-28-31
Average 90 stars, based on 1 article reviews
Multicode Plx Rvp, supplied by EraGen Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multicode-plx/multicode+plx+rvp/pmc03280232-83-28-31
Average 90 stars, based on 1 article reviews
multicode-plx rvp - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Multiplex Assay:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Polymerase Chain Reaction:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Virus:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Microarray:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Quantitative RT-PCR:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Electrophoresis:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Amplification:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Hybridization:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Luminex:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Sequencing:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Real-time Polymerase Chain Reaction:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Nested PCR:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Staining:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Virus Isolation Assay:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), End Point Assay:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Mass Spectrometry:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Cell Culture:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Gene Assay:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Agarose Gel Electrophoresis:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Enzyme-linked Immunosorbent Assay:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Direct Fluorescent Antibody Test:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), Reverse Transcription Polymerase Chain Reaction:Article Title: Utilization of Nucleic Acid Amplification Assays for the Detection of Respiratory Viruses Article Snippet: There are several kits, the Article Title: Timely diagnosis of respiratory tract infections: Evaluation of the performance of the Respifinder assay compared to the xTAG Respiratory Viral Panel assay Article Snippet: A study by Balada-Llasat et al., evaluating the performance of 3 commercial assays for the diagnosis of respiratory viral infections in adults showed that, when compared to culture, the RVP had a sensitivity and specificity of 100% and 91%, compared to Article Title: Molecular diagnosis of respiratory virus infections. Article Snippet: The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/ H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses.. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses.. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. Article Title: Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections Article Snippet: This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the Article Title: Multiparametric technologies for the diagnosis of syndromic infections Article Snippet: The introduction of molecular diagnostics in the management of infectious diseases provides clinical microbiology with tools allowing a faster counterattack in the fight against disease-causing microbes.. However, in light of the multiand polymicrobial origin of infections and frequency of antimicrobial resistance, most currently approved tests impose a limitation on clinicians, essentially due to the number of microbes a single test can identify.. For many life-threatening conditions, where the balance of host-microbe interactions could dramatically shift if an inappropriate or untimely course of treatment is initiated, it would be strategically beneficial if the laboratory could detect and identify the etiology/etiologies of the infection faster and more accurately. Article Title: Evolving Gene Targets and Technology in Influenza Detection Article Snippet: For broader range detection, several emerging techniques based on multiplex PCR have been developed for respiratory pathogen detection, such as xTag ® respiratory virus panel, ResPlex IITM panel v2.0, Article Title: Detection of Respiratory Viruses by Molecular Methods Article Snippet: These tests, plus the ResPlex II (Qiagen), |
